JPH03144364A - Anti-coagulating agent for counting blood cell - Google Patents
Anti-coagulating agent for counting blood cellInfo
- Publication number
- JPH03144364A JPH03144364A JP28271489A JP28271489A JPH03144364A JP H03144364 A JPH03144364 A JP H03144364A JP 28271489 A JP28271489 A JP 28271489A JP 28271489 A JP28271489 A JP 28271489A JP H03144364 A JPH03144364 A JP H03144364A
- Authority
- JP
- Japan
- Prior art keywords
- blood
- salt
- citric acid
- anticoagulant
- edta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003146 anticoagulant agent Substances 0.000 title claims description 34
- 210000000601 blood cell Anatomy 0.000 title abstract description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 42
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical class OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims abstract description 25
- 238000002156 mixing Methods 0.000 claims abstract description 7
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 claims abstract 2
- 229940127219 anticoagulant drug Drugs 0.000 claims description 33
- 238000004820 blood count Methods 0.000 claims description 14
- 210000004369 blood Anatomy 0.000 abstract description 21
- 239000008280 blood Substances 0.000 abstract description 21
- 210000001772 blood platelet Anatomy 0.000 abstract description 19
- -1 ethylene diamine tetraacetate EDTA salt Chemical class 0.000 abstract description 3
- 230000004520 agglutination Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000004043 dyeing Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000005534 hematocrit Methods 0.000 description 9
- 210000003743 erythrocyte Anatomy 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 7
- 206010043554 thrombocytopenia Diseases 0.000 description 7
- 230000007423 decrease Effects 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 description 2
- HLLSOEKIMZEGFV-UHFFFAOYSA-N 4-(dibutylsulfamoyl)benzoic acid Chemical compound CCCCN(CCCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 HLLSOEKIMZEGFV-UHFFFAOYSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000008601 Polycythemia Diseases 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- PDEDQSAFHNADLV-UHFFFAOYSA-M potassium;disodium;dinitrate;nitrite Chemical compound [Na+].[Na+].[K+].[O-]N=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O PDEDQSAFHNADLV-UHFFFAOYSA-M 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- ZNCPFRVNHGOPAG-UHFFFAOYSA-L sodium oxalate Chemical compound [Na+].[Na+].[O-]C(=O)C([O-])=O ZNCPFRVNHGOPAG-UHFFFAOYSA-L 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は血球石数用抗凝固剤に関し、更に詳しくは臨床
検査に際し血小板数の極めて精密な測定を可能とする血
球計数用抗凝固剤に関する。[Detailed Description of the Invention] [Industrial Application Field] The present invention relates to an anticoagulant for blood cell stone counting, and more particularly to an anticoagulant for blood cell counting that enables very precise measurement of platelet counts during clinical tests. .
血球計数用抗凝固剤は血液の凝固を阻止する薬剤であり
、血液または血漿を対象とする検査のために、流動性の
血液を得る目的で使用される。Anticoagulants for blood cell counting are drugs that inhibit blood coagulation, and are used to obtain fluid blood for blood or plasma testing.
従来、抗凝固剤としては、クエン酸、シュウ酸のナトリ
ウム、カリウム、アンモニウム塩液；エチレンジアミン
四酢酸（以下、ＥＤＴＡという）、フッ化ナトリウム、
フン化カリウム、ヘパリン液等が使用されてきた。これ
らの抗凝固剤でも３．８％のクエン酸のナトリウム塩ま
たは０゜ＩＮのシュウ酸のナトリウム塩がしばしば使用
されるが、般に血液９容量に対し１容量が混和されてい
る。Conventionally, anticoagulants include citric acid, sodium, potassium, and ammonium salt solutions of oxalic acid; ethylenediaminetetraacetic acid (hereinafter referred to as EDTA), sodium fluoride,
Potassium fluoride, heparin solution, etc. have been used. Among these anticoagulants, 3.8% citric acid sodium salt or 0° IN oxalic acid sodium salt are often used, and generally one volume is mixed for every nine volumes of blood.
そして、この抗凝固剤はその種類により血液の有形・無
形成分に種々の影響を与えるため、検査に際しては指定
されたものが使用されてきた。Since these anticoagulants have various effects on the tangible and non-formable components of blood depending on their type, designated anticoagulants have been used in tests.
一方、血球計数とは末梢血液単位容積中の血球数（赤血
球数、白血球数、血小板数）を測定することであるが、
この血球計数により、貧血や多血症、白血球の減少や増
加、血小板の減少や増加を知ることができ各種疾患の診
断に役立っている。On the other hand, blood cell counting is the measurement of the number of blood cells (red blood cells, white blood cells, platelets) in a unit volume of peripheral blood.
This blood cell count allows us to know anemia, polycythemia, decrease or increase in white blood cells, decrease or increase in platelets, and is useful in diagnosing various diseases.
例えば、血小板の計数には塗抹標本で赤血球に対する血
小板数の比を求め、同時に赤血球数を算定して計算する
間接法や、８４算板を用いるブレツカ−・クロカイシト
法などの直接法がある。For example, platelet counting includes an indirect method in which the ratio of the number of platelets to red blood cells is obtained from a smear sample and the number of red blood cells is calculated at the same time, and a direct method such as the Bretzker-Krokaisito method using an 84 scale board.
ところで、従来から汎用されてきたＥＤＴＡ塩からなる
血球計数用抗凝固剤は、血小板同士の凝集を招き、血小
板数が少なく測定されるといういわゆる色性血小板減少
が日常しばしば現れる。By the way, anticoagulants for blood cell counting made of EDTA salts that have been widely used in the past often cause aggregation of platelets, resulting in a so-called chromatic thrombocytopenia in which the number of platelets is measured as low.
このような色性血小板減少に対する開発・研究は各所で
様々に進められてきているが、今日まで液中の赤血球容
積比）の変化などの問題点があった。Development and research on such chromatic thrombocytopenia has been carried out in various places, but to date there have been problems such as changes in the red blood cell volume ratio in the fluid.
本発明の目的は上記した問題点の解消にあり、血小板同
士の凝集を阻止すると共に、共存する他の血球（白血球
、赤血球）の大きさ、形態の保持および染色性に変化を
与えない血球計数用抗凝固剤を提供することにある。The purpose of the present invention is to solve the above-mentioned problems, and to provide a blood cell count that prevents the aggregation of platelets and does not change the size, shape, or staining of other coexisting blood cells (white blood cells, red blood cells). The purpose of the present invention is to provide an anticoagulant for use in the medical field.
本発明の血球計数用抗凝固剤は、エチレンジアミン四酢
酸（ＥＤＴＡ）塩とクエン酸からなり、その配合比（前
者／後者）が７ノ１〜１３／１であることを特徴とする
ものである。The anticoagulant for blood cell counting of the present invention is composed of ethylenediaminetetraacetic acid (EDTA) salt and citric acid, and is characterized in that the blending ratio (former/latter) is 7:1 to 13/1. .
本発明の血球計数用抗凝固剤は、通常、血液１１に対し
Ｅ Ｄ ＴＡ塩７ｍｇ／クエン＃１ｎ＋ｇ乃至ＥＤ１’
Ａ塩１３ｍｇ／クエン酸１ｍｇの割合で使用される。The anticoagulant for blood cell counting of the present invention usually contains 7 mg of EDTA salt/Quen #1n+g to ED1' per blood 11.
It is used at a ratio of 13 mg of A salt/1 mg of citric acid.
この配合比が７７１未満ではへマドクリット値が高くな
り、１３／１を超えると逆にヘマトクリット値が低くな
り望ましくない。好ましくは１０／１である。If this blending ratio is less than 771, the hematocrit value will be high, and if it exceeds 13/1, the hematocrit value will be undesirably low. Preferably it is 10/1.
また、ＥＤＴＡ塩用の塩基としては、例えば、カリウム
、ナトリウムが挙げられる。さらに、血球計数には従来
知られた方法が適用でき、例えば、ソーマ（Ｌｈｏｍａ
）式血球計算器、品性式血球計算器、コールタ−（（：
ＨＩｔｅｒ）式血球計算器、エバンス（Ｅｖａｎｓ）式
血球計算器等を用いる方法がある。Furthermore, examples of the base for EDTA salt include potassium and sodium. Furthermore, conventionally known methods can be applied to blood cell counting, such as Soma (Lhoma).
) blood cell counter, quality blood cell counter, Coulter ((:
There is a method using a HIter type hemocytometer, an Evans type hemocytometer, etc.
一般に、臨床検査における血球計数に際しては、血液１
ｍｌに対しＥＤＴＡ塩１ｍｇの割合で使用され、このＥ
ＤＴＡ塩を過剰に添加（例えば、１０倍量乃至３０倍量
）することにより色性血小板減少が消失することは知ら
れている。しかし、この場合はＥＤＴＡ塩の過剰により
浸透圧が上昇し、ヘマトクリット値の低下を招いてしま
う。Generally, when counting blood cells in clinical tests, blood 1
It is used at a ratio of 1 mg of EDTA salt per ml, and this E
It is known that chromatic thrombocytopenia disappears by adding an excessive amount of DTA salt (for example, 10 times to 30 times the amount). However, in this case, the osmotic pressure increases due to excess EDTA salt, leading to a decrease in hematocrit value.
本発明の重要な特徴は、ＥＤＴＡ塩に対しクエン酸を少
量併用することによりヘマトクリット値の低下を防止し
、かつその配合割合を特定の７／１〜１３／ｌとした点
にある。勿論、この配合割合は使用に際し被検物である
血液の量に応じる相対的数量であって、例えば、血液１
ｍｌに対してはＥＤＴＡ塩ｌｏｎｇおよびクエン酸１ｍ
ｇと設定されるものである。The important feature of the present invention is that a decrease in hematocrit value is prevented by using a small amount of citric acid in combination with EDTA salt, and the mixing ratio is set to a specific range of 7/1 to 13/l. Of course, this mixing ratio is a relative quantity depending on the amount of blood that is the test substance in use.
EDTA salt long and citric acid 1 m per ml
g.
つぎに、本発明を添付した図面に基づいて説明する。Next, the present invention will be explained based on the attached drawings.
第１図は、従来のＥＤＴＡ塩からなる抗凝固剤の性能を
示す図である。すなわち、ＥＤＴＡ塩の添加量を変化さ
せてヘマトクリット値の変化を示したものであり、ＥＤ
ＴＡ塩が血液１１に対しｌ１１１ｇである場合にはへマ
ドクリット値は４５％であるが、ＥＤＴＡ塩を５０１ｇ
、ｌ１０ｌｌ１．１５ｍｇと順次増していくとヘマトク
リット値はそれぞれ４３．５％、４２％、４１％と低下
している。FIG. 1 is a diagram showing the performance of a conventional anticoagulant consisting of an EDTA salt. In other words, it shows the change in hematocrit value by changing the amount of EDTA salt added, and the ED
If TA salt is 111 g per blood 11, the hemadcrit value is 45%, but if EDTA salt is 501 g
, l10ll1.15mg, the hematocrit values decreased to 43.5%, 42%, and 41%, respectively.
この第１図から明らかなように、ＥＤＴＡ塩量の増加は
確かに色性血小板減少を消失させるが、同時にヘマトク
リット値の低下を招き、血液の臨床検査における精密な
データとは言えなくなる。As is clear from FIG. 1, an increase in the amount of EDTA salt does indeed eliminate chromatic thrombocytopenia, but at the same time it causes a decrease in the hematocrit value, which cannot be said to be accurate data in clinical blood tests.
第２図はクエン酸ＩＢに対しＥ Ｄ ’ｒＡ塩の配合割
合を変化させた場合のへマドクリット値の変化を示す図
である。すなわち、血液１ｍｌにクエン酸ＩＢを加え、
ＥＤＴＡ塩の配合量を２．４２Ｑｍｇと変化させていく
と、ＥＤＴＡ塩１０ｍｇおよびクエン酸１ｍｇの割合で
ヘマトクリット値に変化のないことが確認された。FIG. 2 is a graph showing changes in the hemadcrit value when the blending ratio of ED'rA salt to IB citrate was changed. That is, add IB citrate to 1 ml of blood,
When the amount of EDTA salt was changed to 2.42Qmg, it was confirmed that there was no change in the hematocrit value at a ratio of 10 mg of EDTA salt and 1 mg of citric acid.
第３図は偽性血小板減少者の検体において本発明のＥＤ
ＴＡ塩及びクエン酸からなる抗凝固剤と従来のＥＤＴＡ
塩からなる抗凝固剤とを比較した図である。すなわち、
血液１ｍｌに対し、ＥＤＴＡ塩１０ｍｇ及びクエン酸Ｉ
Ｂからなる本発明の抗凝固剤は偽性血小板減少者におけ
る血小板数の経時的測定値に変化がなく、これに対しＥ
ＤＴＡ塩ｌＩＩｇからなる従来の抗凝固剤は血小板数の
著しい低下があることが理解される。Figure 3 shows the ED of the present invention in specimens from patients with pseudothrombocytopenia.
Anticoagulant consisting of TA salt and citric acid and conventional EDTA
It is a figure comparing with an anticoagulant consisting of a salt. That is,
10 mg of EDTA salt and I citric acid per 1 ml of blood
The anticoagulant of the present invention consisting of B has no change in platelet count over time in patients with pseudothrombocytopenia, whereas E
It is understood that the conventional anticoagulant consisting of DTA salt lIIg has a significant reduction in platelet counts.
以下に、本発明の実施例及び比較例を挙げ更に詳しく説
明する。EXAMPLES Below, Examples and Comparative Examples of the present invention will be given and explained in more detail.
１〜７ び １〜７
仏性血小板減少症から採血した血液２ｍ１（７症例）を
用意し、本発明の抗凝固剤（Ｆ、 Ｄ Ｔ ＡのＮａ塩
：１０ｍｇ、クエンｆｉ：１ｍｇ）を加え、コールタ−
大計算器（コールタ−・カウンター社製、モデルＳ＋Ｓ
）により血小板数を測定した。結果を第４図に示す。1-7 and 1-7 Prepare 2 ml of blood (7 cases) collected from French thrombocytopenia, add the anticoagulant of the present invention (F, DTA Na salt: 10 mg, Quen fi: 1 mg), coulter
Large calculator (manufactured by Coulter Counter, model S+S
) The platelet count was measured. The results are shown in Figure 4.
一方、同じ血液２ｍ１（７症例）を用意し、比較用の抗
凝固剤（ＥＤＴＡのＮａ塩：１ｍｇ）を加えコールタ−
大計算器により血小板数を測定した。結果を第４図に併
せて示す。On the other hand, 2 ml of the same blood (7 cases) was prepared, an anticoagulant for comparison (EDTA Na salt: 1 mg) was added, and a Coulter
Platelet counts were measured using a large calculator. The results are also shown in Figure 4.
なお、血液中の血小板数の目安として、ユノベノト法に
より上記各７症例の血液について採血直後の血小板数を
測定した。結果を第４図に併せて示す。As a measure of the number of platelets in blood, the number of platelets was measured immediately after blood collection from each of the seven cases described above using the Unovenot method. The results are also shown in Figure 4.
ただし、実施例１〜７及び比較例１〜７の稙は採血時か
ら３時間経過後の値である。However, the values for Examples 1 to 7 and Comparative Examples 1 to 7 are the values 3 hours after blood collection.
第４図から明らかな通り、従来の抗凝固剤では仏性血小
板減少現象の現れにより血小板数が著しく減少している
が、本発明の抗凝固剤では採血直後にユノペット法によ
り測定した血小板数とほとんど差異がなく、臨床検査に
用いて極めて正確なデータを提供できることが理解され
る。As is clear from Figure 4, with conventional anticoagulants, the platelet count significantly decreases due to the manifestation of the French thrombocytopenia phenomenon, but with the anticoagulant of the present invention, the platelet count is almost the same as that measured by the Yunopet method immediately after blood collection. It is understood that there is no difference and that it can be used in clinical tests to provide extremely accurate data.
更に、本発明の抗凝固剤が臨床検査における他の測定項
目にも影響を与えないことを示すため、健常人から採血
した血液１ｍｌを用意し、本発明及び従来の抗凝固剤を
用い、白血球数、赤血球数、ヘモグロビン濃度及びヘマ
トクリット値について、採血後１０分から２４時間まで
の間に５回測定した。結果を第１表及び第２表に示す。Furthermore, in order to demonstrate that the anticoagulant of the present invention does not affect other measurement items in clinical tests, 1 ml of blood collected from a healthy person was prepared, and the anticoagulant of the present invention and the conventional anticoagulant were used to determine white blood cells. The blood count, red blood cell count, hemoglobin concentration, and hematocrit value were measured five times from 10 minutes to 24 hours after blood collection. The results are shown in Tables 1 and 2.
（以下余白、次頁につづく。）
第 １ 表 （本発明）
第１表及び第２表より明らかなように、両者の測定値に
ほとんど差がなく、本発明の抗凝固剤が臨床検査におけ
る他の測定項目には影響を与えないことが理解される。(The following margins are continued on the next page.) Table 1 (The present invention) As is clear from Tables 1 and 2, there is almost no difference in the measured values between the two, and the anticoagulant of the present invention is effective in clinical tests. It is understood that other measurement items are not affected.
第 ２ 表 （従来）
〔発明の効果〕
以上に詳述した通り、本発明の血球計数用抗凝固剤は血
小板同士の凝集によるいわゆる仏性血小板減少を排除す
ると共に、共存する他の血球（白血球、赤血球）の大き
さ、形態の保持および染色性に変化を与えないため、血
液の臨床検査における血球計数に用いて精密な計測結果
を与えるものであり、その工業的価値は極めて大である
。Table 2 (Conventional) [Effects of the Invention] As detailed above, the anticoagulant for blood cell counting of the present invention eliminates so-called French thrombocytopenia caused by aggregation of platelets, and also eliminates coexisting other blood cells (white blood cells, Because it does not change the size, shape retention, or stainability of red blood cells (erythrocytes), it is used in blood cell counting in clinical blood tests to provide accurate measurement results, and its industrial value is extremely large.
第１図は従来のＥＤＴＡ塩からなる抗凝固剤を次第に多
く添加した場合のへマドクリット値の変化を示す図であ
る。第２図はクエン酸ＩＢに対しＥＤＴＡ塩の量を変化
させた場合のへマドクリット値の変化を示す図である。
第３図は偽性血小板減少者の検体における本発明のＥＤ
ＴＡ塩及びクエン酸からなる抗凝固剤と従来のＥＤＴＡ
塩からなる抗凝固剤との性能を比較した図である。なお
、Ａは本発明の抗凝固剤を表し、Ｂは従来の抗凝固剤を
表す。第４図は偽性血小板減少者の血液を用いて本発明
の抗凝固剤と従来の抗凝固剤との性能を比較した図であ
る。なお、図中のユノペソト法による測定値は血液中の
血小板数に関する真の値を示す。FIG. 1 is a diagram showing the change in hemadcrit value when a conventional anticoagulant consisting of EDTA salt is added in increasing amounts. FIG. 2 is a graph showing the change in hemadcrit value when the amount of EDTA salt is changed with respect to IB citrate. Figure 3 shows the ED of the present invention in samples from pseudothrombocytopenia patients.
Anticoagulant consisting of TA salt and citric acid and conventional EDTA
It is a figure comparing the performance with an anticoagulant consisting of a salt. Note that A represents the anticoagulant of the present invention, and B represents a conventional anticoagulant. FIG. 4 is a diagram comparing the performance of the anticoagulant of the present invention and a conventional anticoagulant using the blood of a person with pseudothrombocytopenia. In addition, the measured value by the unopest method in the figure shows the true value regarding the number of platelets in the blood.
Claims (1)
合比（前者／後者）が７／１〜１３／１であることを特
徴とする血球計数用抗凝固剤。An anticoagulant for blood cell counting, comprising ethylenediaminetetraacetate and citric acid, and having a blending ratio (former/latter) of 7/1 to 13/1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1282714A JPH0695092B2 (en) | 1989-10-30 | 1989-10-30 | Anticoagulant for blood cell counting |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1282714A JPH0695092B2 (en) | 1989-10-30 | 1989-10-30 | Anticoagulant for blood cell counting |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH03144364A true JPH03144364A (en) | 1991-06-19 |
| JPH0695092B2 JPH0695092B2 (en) | 1994-11-24 |
Family
ID=17656089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1282714A Expired - Lifetime JPH0695092B2 (en) | 1989-10-30 | 1989-10-30 | Anticoagulant for blood cell counting |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0695092B2 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0755800A (en) * | 1993-07-23 | 1995-03-03 | Becton Dickinson & Co | Blood-gathering apparatus |
| EP2522999A1 (en) | 2011-05-10 | 2012-11-14 | Horiba, Ltd. | Reagent for blood cell counting and blood analysis method |
| WO2015102482A1 (en) * | 2013-12-30 | 2015-07-09 | Universiti Putra Malaysia | An anticoagulant |
| CN112964864A (en) * | 2021-02-06 | 2021-06-15 | 郭小旦 | Blood anticoagulation method based on sodium citrate dihydrate and diethylenetriaminepentaacetic acid |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6018762A (en) * | 1983-06-06 | 1985-01-30 | オ−ソ・ダイアグノステイツク・システムズ・インコ−ポレ−テツド | Stabilized coagulation check test |
| JPS618386A (en) * | 1984-06-22 | 1986-01-16 | Mitsubishi Paper Mills Ltd | Gradated thermal transfer recording material |
| JPS62242854A (en) * | 1986-04-15 | 1987-10-23 | Kyoto Ikagaku Kenkyusho:Kk | Method for inhibiting agglutination of platelet of blood |
| JPS62276460A (en) * | 1986-05-23 | 1987-12-01 | Kyoto Ikagaku Kenkyusho:Kk | Method for fractionating and measuring blood platelet by activation type |
-
1989
- 1989-10-30 JP JP1282714A patent/JPH0695092B2/en not_active Expired - Lifetime
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6018762A (en) * | 1983-06-06 | 1985-01-30 | オ−ソ・ダイアグノステイツク・システムズ・インコ−ポレ−テツド | Stabilized coagulation check test |
| JPS618386A (en) * | 1984-06-22 | 1986-01-16 | Mitsubishi Paper Mills Ltd | Gradated thermal transfer recording material |
| JPS62242854A (en) * | 1986-04-15 | 1987-10-23 | Kyoto Ikagaku Kenkyusho:Kk | Method for inhibiting agglutination of platelet of blood |
| JPS62276460A (en) * | 1986-05-23 | 1987-12-01 | Kyoto Ikagaku Kenkyusho:Kk | Method for fractionating and measuring blood platelet by activation type |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0755800A (en) * | 1993-07-23 | 1995-03-03 | Becton Dickinson & Co | Blood-gathering apparatus |
| EP2522999A1 (en) | 2011-05-10 | 2012-11-14 | Horiba, Ltd. | Reagent for blood cell counting and blood analysis method |
| JP2012237605A (en) * | 2011-05-10 | 2012-12-06 | Horiba Ltd | Reagent for blood cell counting and blood analysis method |
| US8927228B2 (en) | 2011-05-10 | 2015-01-06 | Horiba, Ltd. | Reagent for blood cell counting and blood analysis method |
| WO2015102482A1 (en) * | 2013-12-30 | 2015-07-09 | Universiti Putra Malaysia | An anticoagulant |
| CN112964864A (en) * | 2021-02-06 | 2021-06-15 | 郭小旦 | Blood anticoagulation method based on sodium citrate dihydrate and diethylenetriaminepentaacetic acid |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0695092B2 (en) | 1994-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Buttarello et al. | The new reticulocyte parameter (RET-Y) of the Sysmex XE 2100: its use in the diagnosis and monitoring of posttreatment sideropenic anemia | |
| McLaren et al. | Regulation of intestinal iron absorption and mucosal iron kinetics in hereditary hemochromatosis | |
| US4264470A (en) | Selecting goat erythrocytes to simulate human platelets in hematologic reference controls | |
| Fehr et al. | Comparison of red cell creatine level and reticulocyte count in appraising the severity of hemolytic processes | |
| Alperin et al. | Hemoglobin A2 levels in health and various hematologic disorders | |
| Koepke et al. | Pre-instrumental variables in coagulation testing | |
| Ahluwalia et al. | Markers of masked iron deficiency and effectiveness of EPO therapy in chronic renal failure | |
| IE41665B1 (en) | Multi-purpose diluent for use in blood analysis by electronic instrumentation | |
| Biggs et al. | The errors of some haematological methods as they are used in a routine laboratory | |
| Brittin et al. | Evaluation of the Coulter counter model S | |
| Gunn et al. | Potassium permeability in β-thalassemia minor red blood cells | |
| Castle et al. | Susceptibility of erythrocytes to hypotonic hemolysis as a function of discoidal form | |
| Brittin et al. | Stability of blood in commonly used anticoagulants: use of refrigerated blood for quality control of the Coulter Counter Model S | |
| JPH03144364A (en) | Anti-coagulating agent for counting blood cell | |
| JP3929283B2 (en) | Bone marrow nucleated cell classification and counting method | |
| Tyler et al. | Hematologic values in horses and interpretation of hematologic data | |
| Rowley | The diagnosis of beta‐thalassemia trait: A review | |
| Wong | Hematology analyzers: special considerations for pediatric patients | |
| Hellerstein et al. | Hemoglobin concentration and erythrocyte cation content | |
| McNulty et al. | Evaluation of STAT-CRIT® hematocrit determination in comparison to Coulter and centrifuge: the effects of isotonic hemodilution and albumin administration | |
| Grant et al. | Red cell changes in chronic pulmonary insufficiency | |
| Posteraro Jr et al. | The diagnostic significance of a prolonged erythrocytic glycerol lysis time (GLT50) | |
| Kim et al. | Inclusions in red blood cells containing Hb S or Hb C | |
| Little et al. | Current concepts of pathogenesis of diabetic retinopathy: a dysproteinemia. | |
| Gordon | Evaluation of a semi-micro method for measuring platelet aggregation in whole blood samples |